|
|
|
| Pathological study of gastrointestinal complications in scleroderma model mice induced by different concentrations of Bleomycin |
| HUANG Yi1 LI Yongqiang1 ZHANG Yilin1 LYU Junying2 |
1.The First College of Clinical Medicine, Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning 530021, China;
2.Department of Traditional Chinese Medicine, the First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning 530021, China
|
|
|
|
Abstract Objective To investigate the pathological study of gastrointestinal complications induced by different concentrations of Bleomycin (BLM) in scleroderma model mice. Methods A total of 18 female BALB/c mice were divided into control group, model group 1, and model group 2 by random number table method, with six mice in each group. The control group were injected with 0.1 ml phosphate buffered saline subcutaneously on the back; the model group 1 were injected 0.1 ml 200 μg/ml BLM; the model group 2 were injected 0.1 ml 500 μg/ml BLM. Three groups were continuously injected for 28 days, once per day. On the 28th day, the mice were sacrificed, and the pathological features of the skin in the injected area, the esophagus, and the small intestinal tissue were observed. The serum levels of D-lactic acid (D-LA) and diamine oxidase (DAO) were gavaged. Results The dermis thickness in model group 1 and model group 2 were thicker than those in the control group (P＜0.05), and the dermis thickness of model group 2 was thicker than that in model group 1(P＜0.05). The collagen volume scores of the esophageal and small intestinal in model group 1 and model group 2 were higher than those in the control group (P＜0.05), and the esophageal collagen volume scores in model group 2 were higher than those in model group 1(P＜0.05). The serum levels of D-LA and DAO in model group 1 and model group 2 were higher than those in the control group (P＜0.05), while the serum levels of D-LA and DAO in model group 2 were higher than those in model group 1 (P＜0.05). Conclusion Both modeling methods can show inflammatory infiltration and fibrotic changes in skin and intestine, and the 500 μg/ml BLM-induced scleroderma model has more obvious changes in skin and intestinal pathological.
|
|
|
|
|
|
[1] Sabrina P，Greta P，Carlotta S，et al. Nutritional Status and Bone Microarchitecture in a Cohort of Systemic Sclerosis Patients [J]. Nutrients，2020，12（6）：1632.
[2] Hughes M，Herrick AL. Systemic sclerosis [J]. Br J Hosp Med （Lond），2019，80（9）：530-536.
[3] Ahuja NK，Clarke JO. Scleroderma and the Esophagus [J]. Gastroenterol Clin North Am，2021，50（4）：905-918.
[4] Sandqvist G，Hesselstrand R. Validity of the Swedish version of the systemic sclerosis quality of life questionnaire（SSCQoL）：A novel measure of quality of life for patients with systemic sclerosis [J]. Ann Rheum Dis，2019，78（6）：855-857.
[5] Ruzehaji N，Avouac J，Elhai M，et al. Combined effect of genetic background and gender in a mouse model of bleomycin- induced skin fibrosis [J]. Arthritis Res Ther，2015，17：145.
[6] 戴才俊，夏晓茹，吴佩亮，等.活性氧簇诱导硬皮病小鼠模型时效性的基础研究[J].医学研究杂志，2016，45（4）：80-84.
[7] Teodoro WR，de Jesus QZ，Dos SL，et al. Proposition of a novel animal model of systemic sclerosis induced by type Ⅴ collagen in C57BL/6 mice that reproduces fibrosis，vasculopathy and autoimmunity [J]. Arthritis Res Ther，2019，21（1）：278.
[8] Stawski L，Han R，Bujor AM，et al. Angiotensin Ⅱ induces skin fibrosis：a novel mouse model of dermal fibrosis [J]. Arthritis Res Ther，2012，14（4）：R194.
[9] Frech TM，Diane Mar. Gastrointestinal and Hepatic Disease in Systemic Sclerosis [J]. Rheum Dis Clin North Am，2018， 44（1）：15-28.
[10] Sornlek W，Sae-Tang K，Watcharawipas A，et al. D-Lactic Acid Production from Sugarcane Bagasse by Genetically Engineered Saccharomyces cerevisiae [J]. J Fungi （Basel），2022，8（8）：816.
[11] Karer M，Ragerresch M，Haider T，et al. Diamine oxidase knockout mice are not hypersensitive to orally or subcutaneously administered histamine [J]. Inflam Res，2022，71（4）：497-511.
[12] Pietrangeli P，Seguella L，Annunziata G，et al. Lathyrus sativus diamine oxidase counteracts histamine-induced cell proliferation，migration and pro-angiogenic mediators release in human colon adenocarcinoma cell line Caco-2 [J]. Phytother Res，2019，33（7）：1878-1887.
[13] Xue M，Ji X，Liang H，et al. The effect of fucoidan on intestinal flora and intestinal barrier function in rats with breast cancer [J]. Food Funct，2018，9（2）：1214-1223.
[14] Blyszczuk P，Kozlova A，Guo Z，et al. Experimental Mouse Model of Bleomycin-Induced Skin Fibrosis [J]. Curr Protoc Immunol，2019，126（1）：e88.
[15] Walters DM，Kleeberger SR. Mouse models of bleomycin- induced pulmonary fibrosis [J]. Curr Protoc Pharmacol，2008，Chapter 5：Unit 5.46.
[16] Truchetet ME，Brembilla NC，Chizzolini C. Current Concepts on the Pathogenesis of Systemic Sclerosis [J]. Clin Rev Allergy Immunol，2021（prepublish）：1-22.
[17] Murtaugh MA，Frech TM. Nutritional status and gastrointestinal symptoms in systemic sclerosis patients [J]. Clin Nutr，2013，32（1）：130-135.
[18] Luquez-Mindiola A，Atuesta AJ，Gomez-Aldana AJ. Gastrointestinal manifestations of systemic sclerosis：An updated review [J]. World J Clin Cases，2021，9（22）：6201-6217.
[19] De Almeida CS，Porel T，Mounie M，et al. Sine scleroderma，limited cutaneous，and diffused cutaneous systemic sclerosis survival and predictors of mortality [J]. Arthritis Res Ther，2021，23（1）：295.
[20] 王修远，杨骥.系统性硬皮病的治疗现状及进展[J].临床皮肤科杂志，2021，50（9）：565-569.
[21] Roberts CG，Hummers LK，Ravich WJ，et al. A case-control study of the pathology of oesophageal disease in systemic sclerosis（scleroderma）[J]. Gut，2006，55（12）：1697- 1703.
[22] Frech TM，Mar D. Gastrointestinal and Hepatic Disease in Systemic Sclerosis [J]. Rheum Dis Clin North Am，2018，44（1）：15-28.
[23] Yamamoto T. Intradermal Injections of Bleomycin to Model Skin Fibrosis [J]. Methods Mol Biol，2017，1627：43-47.
[24] Yamamoto Y，Okano T，Yamada H，et al. Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis [J]. Arthritis Res Ther，2021，23（1）：133.
[25] 陆晓凤，罗婧莹.硬皮病动物模型建模药物最适浓度探讨[J].中国现代医学杂志，2016，26（1）：1-4.
[26] 梁娟，祁承林，胡谋波，等.红花水煎液对系统性硬皮病小鼠皮肤及肺组织纤维化的影响及机制[J].山东医药，2016，56（12）：16-19.
[27] 周雪艳，吕军影.博来霉素诱导建立硬皮病模型小鼠的肠道受累情况分析研究[J].内科，2021，16（2）：142-145. |
|
|
|
